Nuvalent, Inc.
Nuvalent is a company focused on developing selective medicines for cancer treatment, with a team of experienced scientists and industry veterans. The role involves competitive intelligence activities in oncology, supporting decision-making and strategy development across the organization.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2017
Nuvalent, now a part of GSK following an acquisition completed in July 2026, is an oncology company that creates precisely targeted small-molecule therapies using deep expertise in chemistry and structure-based drug discovery. Its pipeline focuses on selective kinase inhibitors for genetically defined cancers, including ALK, ROS1, and HER2-driven solid tumors, with the goal of overcoming resistance and improving patient outcomes. The company has an approved therapy for locally advanced ROS1-positive non-small cell lung cancer, with lead programs including NVL-520, NVL-655, and NVL-330.
Nuvalent Appoints Ron Squarer to Board of Directors
Dec 10, 2025
American Century Companies Inc. Sells 11,767 Shares of Nuvalent, Inc. $NUVL
4 days ago
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Nuvalent, Inc..
39% above the average for this role
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight
2 weeks ago
VP, Head of Research US Oncology
Servier
Director, Clinical Development
Revolution Medicines
Director, Medical Science Liaison (Boston, RI, NH, VT, ME)
Revolution Medicines
Principal Research Associate
Genmab
Director, Competitive Intelligence & Insights - Oncology
Vir Biotechnology
Senior Medical Director
Revolution Medicines